VIVANI MED.INC. NEW O.N. (U5P) - Total Liabilities
Based on the latest financial reports, VIVANI MED.INC. NEW O.N. (U5P) has total liabilities worth €23.66 Million EUR (≈ $27.66 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore VIVANI MED.INC. NEW O.N. (U5P) cash flow conversion to assess how effectively this company generates cash.
VIVANI MED.INC. NEW O.N. - Total Liabilities Trend (2021–2025)
This chart illustrates how VIVANI MED.INC. NEW O.N.'s total liabilities have evolved over time, based on quarterly financial data. See VIVANI MED.INC. NEW O.N. shareholders equity for net asset value and shareholders' equity analysis.
VIVANI MED.INC. NEW O.N. Competitors by Total Liabilities
The table below lists competitors of VIVANI MED.INC. NEW O.N. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Meiwu Technology Co Ltd
NASDAQ:WNW
|
USA | $1.73 Million |
|
Noble Development Public Company Limited
BK:NOBLE
|
Thailand | ฿18.06 Billion |
|
Falcon Metals Ltd
AU:FAL
|
Australia | AU$1.12 Million |
|
Vera Bradley Inc
NASDAQ:VRA
|
USA | $115.62 Million |
|
RGB International Bhd
KLSE:0037
|
Malaysia | RM432.90 Million |
|
BTCS Inc
NASDAQ:BTCS
|
USA | $73.45 Million |
|
Anfield Energy Inc.
NASDAQ:AEC
|
USA | $37.29 Million |
|
VirnetX Holding Corp Common Stock
NYSE:VHC
|
USA | $8.65 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down VIVANI MED.INC. NEW O.N.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see VIVANI MED.INC. NEW O.N. stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.50 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.60 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how VIVANI MED.INC. NEW O.N.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for VIVANI MED.INC. NEW O.N. (2021–2025)
The table below shows the annual total liabilities of VIVANI MED.INC. NEW O.N. from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €23.66 Million ≈ $27.66 Million |
-1.20% |
| 2024-12-31 | €23.95 Million ≈ $28.00 Million |
-4.33% |
| 2023-12-31 | €25.04 Million ≈ $29.27 Million |
+266.99% |
| 2022-12-31 | €6.82 Million ≈ $7.98 Million |
+128.31% |
| 2021-12-31 | €2.99 Million ≈ $3.49 Million |
-- |
About VIVANI MED.INC. NEW O.N.
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the t… Read more